
|Articles|March 31, 2022
Daily Medication Pearl: Polyethylene Glycol 3350 (Golytely)
Author(s)Saro Arakelians, PharmD
Golytely is indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults.
Advertisement
Medication Pearl of the Day: Polyethylene Glycol 3350 (Golytely)
Indication: Golytely is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults.
Insight:
- Dosing: Early in the evening prior to colonoscopy, obtain a food grade container with a volume of at least 1 gallon. After cutting open the packet, pour the entire contents into the container. Add lukewarm water to bring the volume of solution to 1 gallon. After capping container, shake vigorously several times. Instruct patients to consume water or clear liquids during and after bowel preparation up until 2 hours before time of colonoscopy
- Dosage forms: For oral solution: polyethylene glycol 3350 227.1 grams, sodium sulfate (anhydrous) 21.5 grams, sodium bicarbonate 6.36 grams, sodium chloride 5.53 grams, potassium chloride 2.82 grams; supplied in 1-gallon packet.
- Adverse events: Most common adverse reactions (≥3%) are nausea, abdominal fullness, and bloating. Abdominal cramps, vomiting, and anal irritation occur less frequently.
- Mechanism of action: The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.
- Manufacturer: Braintree Laboratories
Sources
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
UConn’s Medical Writing Certificate Program: It’s Just "Write"
3
Pharmacy Policy Updates for October 2025
4
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
5